|Day Low/High||0.03 / 0.03|
|52 Wk Low/High||0.01 / 0.15|
Amarantus-sponsored training for Phase 2 severe burn trial completed with U.S. Army clinical site in late April
OTC Markets Group, President and CEO R. Cromwell Coulson, will speak on panel "Understanding Reg A+ and the 'Mini IPO'"
Companies to hold a Conference Call to discuss the business combination today, March 7, 2015 at 4:30pm ET
Patent issuance will provide intellectual property protection in China for protein therapy, gene therapy and cell therapy applications of MANF
Patent issuance will provide additional IP protection for eltoprazine, lead product candidate, through 2027